Effects of growth factors on an intestinal epithelial cell line: Transforming growth factor β inhibits proliferation and stimulates differentiation

doi:10.1016/0006-291X(87)91481-1

Biochemical and Biophysical Research Communications

Volume 142, Issue 3, 13 February 1987, Pages 775-782

https://doi.org/10.1016/0006-291X(87)91481-1 Get rights and content

Abstract

The effects of epidermal growth factor transforming growth factor β (TGFβ) and other growth factors on the proliferation and differentiation of a cell line derived from rat intestinal crypt epithelium (IEC-6) were defined. Incorporation of [³H]-thymidine was stimulated 1.4–2.4 fold by insulin, insulin like growth factor (IGF), platelet derived growth factor (PDGF), epidermal growth factor (EGF) and 2% fetal calf serum (FCS) respectively. Additive stimulation was observed when FCS was supplemented by insulin, IGF-I or PDGF but not EGF. Incorporation of [³H]-thymidine by IEC-6 was strongly inhibited by TGFβ with greater than 80% inhibition of incorporation at concentration ≅ 2.0 pM. IEC-6 cells bound 4.1±0.15×10⁴ molecules TGFβ/cell and appeared to have only a single class of high affinity receptors (Kd ≅ 0.5 pM). TGFβ inhibition was unaffected by the presence of insulin or IGF-I suggesting it inhibits proliferation at a step subsequent to that at which these growth factors stimulate [³H]-thymidine incorporation. TGFβ also reduced the stimulation induced by FCS by 65%. In contrast EGF reduced TGFβ inhibition by 60%. IEC-6 cells demonstrated the appearance of sucrase activity after > 18 hours treatment with TGFβ. These findings suggest that TGFβ may inhibit proliferative activity and promote the development of differentiated function in intestinal epithelial cells.

References (19)

H. Quastler et al.
Exp. Cell Res
(1959)
J. Massague
J. Biol. Chem
(1984)
M. Frater-Schroder et al.
Biochem. Biophys. Res. Commun
(1986)
J.J. Feige et al.
Biochem. Biophys. Res. Commun
(1986)
C.A. Frolik et al.
J. Biol. Chem
(1984)
M.M. Weiser
J. Biol. Chem
(1973)
M. Messer et al.
Anal. Biochem
(1966)
O.H. Lowry et al.
J. Biol. Chem
(1951)
E. Ruff et al.
Biophys. Biochem. Res. Commun
(1986)

There are more references available in the full text version of this article.

Cited by (275)

From machine learning to deep learning: Advances of the recent data-driven paradigm shift in medicine and healthcare
2024, Current Research in Biotechnology
The medicine and healthcare sector has been evolving and advancing very fast. The advancement has been initiated and shaped by the applications of data-driven, robust, and efficient machine learning (ML) to deep learning (DL) technologies. ML in the medical sector is developing quickly, causing rapid progress, reshaping medicine, and improving clinician and patient experiences. ML technologies evolved into data-hungry DL approaches, which are more robust and efficient in dealing with medical data. This article reviews some critical data-driven aspects of machine intelligence in the medical field. In this direction, the article illustrated the recent progress of data-driven medical science using ML to DL in two categories: firstly, the recent development of data science in medicine with the use of ML to DL and, secondly, the chabot technologies in healthcare and medicine, particularly on ChatGPT. Here, we discuss the progress of ML, DL, and the transition requirements from ML to DL. To discuss the advancement in data science, we illustrate prospective studies of medical image data, newly evolved DL interpretation data from EMR or EHR, big data in personalized medicine, and dataset shifts in artificial intelligence (AI). Simultaneously, the article illustrated recently developed DL-enabled ChatGPT technology. Finally, we summarize the broad role of ML and DL in medicine and the significant challenges for implementing recent ML to DL technologies in healthcare. The overview of the data-driven paradigm shift in medicine using ML to DL technologies in the article will benefit researchers immensely.
Bioactive photocrosslinkable resin solely based on refined decellularized small intestine submucosa for vat photopolymerization of in vitro tissue mimics
2023, Additive Manufacturing
Three-dimensionally (3D) printed tissue mimics are unique in vitro platforms for studying human pathophysiology in a more physiologically relevant manner compared to oversimplified 2D cell cultures and complex animal models. However, their 3D printing requires an availability of materials that at the same time show a high level of biomimicry and also have a suitable viscosity profile and crosslinking kinetics for the desired printing technique. We developed a new biomimetic material for vat photopolymerization by solubilizing and functionalizing porcine small intestine submucosa (dSIS) into photocrosslinkable dSIS methacryloyl (dSIS-MA) and by subsequently formulating it into a bioactive 3D printing resin. The concentration of 1.5 wt% of dSIS-MA yielded desired viscosity and photocrosslinking kinetics, and the 3D printing of the resin resulted in fully transparent and highly swelling dSIS-MA hydrogels with a stiffness resembling native intestinal tissue. The new dSIS-MA resin was successfully 3D printed into acellular intestine-mimicking scaffolds that desirably guided the seeded human intestinal cells to grow along the 3D villi mimics. Human small intestinal organoid-derived undifferentiated primary cells grew to confluency on the dSIS-MA hydrogels and formed continuous tight junctions, thereby demonstrating the suitability of the 3D printing material for growing intestinal epithelium mimics. Furthermore, a small fraction of the human primary intestinal cells produced mucin 5AC, demonstrating early differentiation of these cells on the dSIS-MA hydrogels. The excellent cell compatibility of the dSIS-MA material combined with its high printability and biomimicry indicated that this new resin can be a great help in modelling and reproducing native tissue architectures where enhanced physiological relevancy is desired.
Genomic alterations in signet ring and mucinous patterned colorectal carcinoma
2019, Pathology Research and Practice
The genetic alterations (GAs) in two specific histological subtypes of colorectal cancer (CRC), signet ring cell colorectal carcinoma (SRC) and mucinous colorectal carcinoma (MC), are not well known. In the present study, we employed next-generation sequencing to perform genetic profiling of SRC and MC, and compared the spectrum of GAs with the alterations found in conventional type colorectal cancer (CON).
We selected 46 CRCs comprising 17 SRCs and mucinous carcinoma with signet ring cell component (SRCCs), 17 MCs, and 12 CONs with microsatellite stability or microsatellite instability-low. Deep sequencing was performed using a targeted cancer panel composed of 171 cancer-related genes. SMAD4 protein expression was evaluated by immunohistochemical staining.
We detected 108 mutations in 18 different genes. Overall, 2.34 GAs were detected per tumor (range, 0–14). The overall frequency of GA and alteration in targetable genes was less prevalent in SRC/SRCC compared to the frequency of alteration in MC/CON (p = 0.040 and p < 0.001, respectively). The GA profile of SRC/SRCC included TP53 (8/17, 47.1%), SMAD4 (5/17, 29.4%), KRAS (4/17.23.5%), APC (4/17.23.5%), PIK3CA, ATM, BRAF, and PIK3R1 (1/17, 5.9%, each). KRAS mutation was significantly less prevalent in SRC/SRCC compared to the number of KRAS mutations in MC (12/17, 70.6%) and CON (9/12, 75.0%) (p = 0.015 and 0.01, respectively). Compared to the 152 non-hypermutated CONs from TCGA database, SMAD4 alteration was predominant in SRC/SRCC (p = 0.045) with aberrant loss of SMAD4 expression (13/17, 76.5%) compared to the SMAD4 alterations in CON (5/15, 33.3%) (p = 0.031). Accordingly, KRAS (12/17, 70.6%), APC (6/17, 35.3%), SMAD4, TP53 (4/17, 23.5%, each), PIK3CA (3/17, 17.6%), AKT1, ATM, BRAF, EGFR, and EZH2 (1/17, 5.9%, each) were altered in MC. APC and TP53 mutations were less frequent in MC compared to those in TCGA-CON (p < 0.001 and 0.003, respectively) whereas KRAS mutation was prevalent (p = 0.041).
Alterations of known cancer associated genes and targetable genes in SRC/SRCC are infrequent. The profile of GAs in SRC/SRCC and MC differs from the GA profile of CON. Specifically, SMAD4 mutation and loss of SMAD4 expression is frequently found in SRC/SRCC. The genetic profiles revealed in the present study may aid in developing precision medicine for CRC treatment based on histological subtype.
Network and structure based inference of functional single nucleotide polymorphisms associated with the TGFβ1 gene and its role in colorectal cancer (CRC)
2018, Gene Reports
System level analysis of the cellular signaling processes helps to understand the perturbations due to gene expression or through protein-protein interactions. In the case of colorectal cancer (CRC), a large proportion of patients display mutational inactivation of multiple pathways. Specifically, TGFβ-signaling is postulated to be one of the major contributors among them. The vast variety of studies to date considered the role of TGFβR1 and TGFβR2 receptors in CRC progression and relatively fewer studies targeted the Transforming growth factor-β1 (TGFβ1) protein. Therefore, this remains a poorly understood mechanism. TGFβ1 is the most abundant and universally expressed isoform, which is secreted into the extracellular matrix as a latent protein and is the important regulator of the cellular proliferation. Increased expression of TGFβ1 allows immunogenic cell lines to escape immunosurveillance and thus form tumors. Till date, no study has focused on the complete aspect of the TGFβ1 effects. Here, we investigated the consequences of 37 ns-SNPs in the TGFβ1 gene through computational tools and four ns-SNPs L28F (rs199946261), G46R (rs768250306), N69Y (rs763943753), and L83R (rs541829714) were identified that are highly likely to affect the structure, function, and activity of the TGFβ1 protein. Network motifs were also identified for the concerned pathway in the quest for functional annotation. In our study, we have performed a combination of network and structure-based analysis to elucidate the role of candidate genes for the TGFβ signaling pathway and to infer the mutational effect on the TGFβ1 gene and their relationship towards CRC progression.
Growth Factors in the Intestinal Tract
2018, Physiology of the Gastrointestinal Tract, Sixth Edition
Gastrointestinal (GI) tissues express a multitude of growth factors, broadly defined as naturally occurring polypeptides that elicit cellular growth, proliferation, or differentiation following binding to surface membrane receptors. In the GI tract, growth factors perform functions at all stages of life, and play critical roles in development, maintenance, repair and regeneration, pro- and anticancer functions, and immune cell regulation. In this chapter, we discuss the basic physiological processes by which growth factors operate in GI tissue and the signaling underlying their specific roles in health and disease. We review several families of growth factors that have well-defined and significant roles in the GI tract [epidermal growth factor (EGF), transforming growth factor beta (TGF-β), insulin-like growth factor (IGF), hepatocyte growth factor (HGF), and fibroblast growth factor (FGF)] and briefly discuss several other families with emerging roles.
Exogenous IGF-1 promotes hair growth by stimulating cell proliferation and down regulating TGF-β1 in C57BL/6 mice in vivo
2014, Growth Hormone and IGF Research
Citation Excerpt :
Members of the TGF-β family of growth factors play an important role in the regulation of differentiation, proliferation, apoptosis, and function of a wide variety of cells [14,15]. TGF-β1 may inhibit proliferative activity and promote differentiation in intestinal epithelial cells [16]. According to the report, TGF-β is a possible negative regulator of hair follicle growth [17].
Insulin-like growth factor 1 (IGF-1) increases the growth of cultured hair follicles and plays a role in regulating hair migration during the development of hair follicles in transgenic mice. However, the exogenous effect of IGF-1 on hair growth in wild-type mice has not been reported. In the present study, we examined whether IGF-1 was an important regulator of hair follicle growth in wide-type mice in vivo.
C57BL/6 mice were injected with different concentrations of IGF-1 on dorsal skin. The treated tissues were analyzed by immunoassay methods for TGF-β1 and BrdU.
Local injection of IGF-1 increased hair follicle number and prolonged the growing phase during the transition from anagen to telogen. Meanwhile, immunology analyses revealed that IGF-1 also stimulated the proliferation of follicle cells in anagen of the matrix and down regulated TGF-β1 expression in hair follicles.
These observations suggest that IGF-1 is an effective stimulator of hair follicle development in wide-type mice in vivo and may be a promising drug candidate for baldness therapy.

View all citing articles on Scopus

View full text

Effects of growth factors on an intestinal epithelial cell line: Transforming growth factor β inhibits proliferation and stimulates differentiation

Abstract

Exp. Cell Res

J. Biol. Chem

Biochem. Biophys. Res. Commun

Biochem. Biophys. Res. Commun

J. Biol. Chem

J. Biol. Chem

Anal. Biochem

J. Biol. Chem

Biophys. Biochem. Res. Commun